Radiopharm Theranostics prices unregistered warrants in private placement at US$3.79 per ADS

• Radiopharm Theranostics priced a concurrent private placement of unregistered warrants to buy 1,281,646 ADSs alongside a US$4.1 million registered direct offering.
• Warrants become exercisable after shareholder approval, carry a US$3.79 per ADS exercise price, expire July 31, 2029.
• Separate Australian private placement drew firm commitments for about A$6.7 million; 40,000,000 shares require shareholder approval.
• Shareholder vote expected around September 11, 2026; proceeds earmarked for the RAD101 registrational study, other clinical programs, working capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-081559), on July 27, 2026, and is solely responsible for the information contained therein.